For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...
Phase I study to evaluate the safety and efficacy of switchable CAR-T cell therapy with FY001 and CART001 in patients with refractory CD20-positive B-cell non-Hodgkin lymphoma (EPOC1803). CD4 ≥124.5 ...
Use of Hematopoietic Progenitors in Whole Blood to Support Dose-Dense Chemotherapy: A Randomized Phase II Trial in Small-Cell Lung Cancer Patients PURPOSE: Previous studies in patients with ...
T lymphocytes play a pivotal role in resolving hepatitis B virus infection. This study aimed to investigate the dynamics of peripheral blood T lymphocyte subsets during peginterferon alpha (peg-IFN-α) ...
Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T ...
The next question researchers want to answer is whether urine-derived lymphocytes can actually help inform responses to ...
Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with longer PFS, suggesting T-cell composition may serve as a biomarker to ...
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare subtype of non-Hodgkin lymphoma that frequently presents with multiorgan involvement. We report a diagnostically challenging ...
A review found that CD4/CD8 ratio could be used as a prognostic marker for mortality in patients with HIV, though future studies need to be done to confirm these findings. Clinical practices can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results